Cue Biopharma, Inc. Income Statement
CUE|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Cue Biopharma, Inc. reported $27M in revenue and $27M in net loss for FY2025. Revenue has grown at a 57.5% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.5M | $1.1M | $1.1M |
| SG&A Expense | $16.2M | $14.6M | $16.7M | $16.2M | $17.3M | $12.7M | $11.3M | $4.3M |
| R&D Expense | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M | $27.5M | $28.5M | $18.9M |
| Operating Income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M | -$36.8M | -$38.7M | -$23.2M |
| Interest Expense | $100.0K | $100.0K | $100.0K | $109.0K | - | - | - | - |
| Income Tax | $500.0K | $0 | - | $0 | $495.0K | $412.5K | $825.0K | $825.0K |
| Net Income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M | -$36.7M | -$39.0M | -$23.2M |
| EPS (Basic) | -$0.72 | -$1.11 | -$1.49 | -$1.41 | - | - | - | - |
| EPS (Diluted) | -$0.72 | -$1.11 | -$1.49 | -$1.41 | -$1.56 | -$1.66 | -$1.94 | -$2.16 |
| Shares Outstanding | 61.8M | 47.2M | 47.2M | 32.2M | 30.4M | 26.6M | 20.7M | 19.5M |
| Operating Margin | -96.7% | -446.9% | -949.9% | -4275.1% | -292.6% | -1063.2% | -3386.7% | -2033.4% |
| Profit Margin | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% | -1061.2% | -3411.5% | -2033.4% |